Press Center
Jun 11, 2025
COVID-19,Seasonal influenza

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

May 29, 2025
Corporate and finance

Novavax to Participate in Upcoming Investor Conferences

May 19, 2025
COVID-19

U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine

May 8, 2025
Corporate and finance

Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

Perspectives & Insights

Explore our blog for valuable insights and inspiring stories from our team as we fulfill our vision to spark transformation in global health.

In the News

See what other are saying about Novavax.

Contagion Live

Novavax COVID-19 Vaccine Linked to Fewer Side Effects in Health Care Workers and First Responders

PharmaVoice

The industry heavyweight behind Novavax’s push to bounce back

BioSpace

Two Years Into Novavax Reset, CEO Jacobs Hunts for Silver Lining

BiotechTV

After striking a transformational deal with Sanofi, Novavax is ramping up its vaccine pipeline

Chief Influencer

Silvia Taylor on Championing Science and Staying the Course

Washington Business Journal

The turnaround man, John Jacobs is reshaping Novavax for the post-pandemic era

Note: This section features articles written by external media outlets and journalists.

Media
contact

Phone
(202) 709-5563

Images, videos and files for media use

Resources for members of the press.

About Novavax

We tackle some of the world's most significant health challenges by leveraging our scientific expertise in vaccines and cutting-edge technology platform, including protein-based nanoparticles and Matrix-M® adjuvant.